The Expected Toxicity Rate at the Maximum Tolerated Dose in Bridging Studies in Alzheimer’s Disease
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug Guides,Pharmacology (nursing)
Link
http://link.springer.com/content/pdf/10.1177/009286150503900205.pdf
Reference14 articles.
1. Cutler NR, Sramek JJ. Scientific and ethical concerns in clinical trials in Alzheimer‘s patients: the bridging study. European J Clin Pharmacol. 1995; 48:421–428.
2. Cutler NR, Sramek JJ. The target population in phase I clinical trials of the ’bridging study.’ Alzheimer‘s Disease Assoc Disorder. 1995;9: 139–145.
3. Sramek JJ, Anand R, Wardle TS, Irwin P, Hartman RD, Cutler NR. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer‘s disease. Life Sciences. 1996;58:1201–1207.
4. Bodick NC, Walter Wo, Levey Al, Cutler NR. et al. Effects of xanomeline. a selective muscarinic receptor agonist. on cognitive function and behavioral symptoms in Alzheimer‘s disease. Arch Neuro. 1997;54:465–473.
5. Sramek JJ, Hurley DJ, Wardle TS, Satterwhile JH, Hourani J, Dies F, Culler NR. The safely and tolerabiltly of xanomeline tartrate in patients with Alzheimer‘s disease. J Clin Pharmacol. 1995;35: 800–06.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3